◆ TICKERBASEOpen interactive view →
◆ TICKERBASE · GLOBAL STOCK FINANCIAL DATA LIBRARY

HomeAll stocksG › GRAL

GRAIL, LLC (GRAL) Financial History

20 years of revenue, earnings, cash-flow and balance-sheet history from public filings.

HEALTHCARE · DIAGNOSTICS & RESEARCH · DATA UPDATED 2026-08-28

GRAIL, LLC (GRAL) operates in the DIAGNOSTICS & RESEARCH industry and is headquartered in Menlo Park, United States with about 910 employees. Its market capitalization is roughly $4 billion. In the fiscal year ended 2025-12-31, GRAL reported $147M in revenue and ($408M) in net income.

GRAIL, Inc., a commercial-stage healthcare company, provides multi-cancer early detection testing and services in the United States and internationally.

Interactive charts & full statements → Open the GRAL valuation workbench →

GRAL Revenue & Earnings History — Annual Income Statement

Income statementTTM → 2026-06-302025-12-312024-12-312023-12-312022-12-312021-12-312020-12-312019-12-312018-12-31
Total Revenue$165M$147M$126M$93M$56M$15M$0M
Gross Profit($18M)($63M)($78M)($96M)($116M)($100M)($10M)($14M)
Gross Margin %-10.8%-42.5%-62.1%-102.7%-209.6%-684.4%
Operating Income (EBIT)($559M)($534M)($2.2B)($1.5B)($5.4B)($1.3B)($316M)($256M)($287M)
Operating Margin %-338.4%-363.0%-1743.0%-1627.6%-9798.2%-8659.6%
Net Income($392M)($408M)($2.0B)($1.5B)($5.4B)($1.2B)($312M)($245M)($276M)
Net Margin %-236.9%-277.5%-1613.9%-1574.2%-9719.4%-8539.4%
EBITDA($413M)($378M)($610M)($638M)($588M)($1.2B)($309M)($243M)($269M)
Earnings Per Share (EPS)$-9.75$-11.11$-63.54$-47.20$-173.87$-40.18$-2.52$-1.99$-2.42
Shares Outstanding (M)43M37M32M31M31M31M124M123M114M

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

GRAL Quarterly Revenue & Earnings — Last 8 Quarters

Quarterly income statement2026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-312024-09-30
Total Revenue$45M$41M$44M$36M$36M$32M$38M$29M
Gross Profit($13M)$20M($11M)($14M)($18M)($20M)($16M)($22M)
Gross Margin %-28.1%47.9%-25.5%-37.9%-50.0%-62.6%-41.7%-77.6%
Operating Income (EBIT)($174M)($136M)($124M)($125M)($159M)($154M)($137M)($184M)
Operating Margin %-388.9%-332.9%-285.4%-346.2%-446.9%-482.5%-358.0%-640.5%
Net Income($110M)($93M)($99M)($89M)($114M)($106M)($97M)($126M)
Net Margin %-246.7%-228.5%-227.5%-245.8%-320.7%-333.6%-253.8%-438.7%
EBITDA($167M)($89M)($78M)($80M)($92M)($107M)($88M)($133M)
Earnings Per Share (EPS)$-2.56$-2.29$-2.44$-2.46$-3.25$-3.10$-3.04$-3.94
Shares Outstanding (M)43M41M41M36M35M34M32M32M

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

GRAL Free Cash Flow History

Cash flowTTM → 2026-06-302025-12-312024-12-312023-12-312022-12-312021-12-312020-12-312019-12-312018-12-31
Cash from Operations (CFO)($295M)($299M)($577M)($596M)($561M)($688M)($232M)($246M)($209M)
Capital Expenditures (CapEx)$2M$1M$5M$13M$23M$70M$12M$3M$16M
Free Cash Flow (FCF)($297M)($300M)($582M)($609M)($584M)($758M)($244M)($249M)($225M)
FCF Margin %-179.6%-203.8%-463.7%-653.8%-1051.6%-5187.9%

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

GRAL Quarterly Free Cash Flow — Last 8 Quarters

Quarterly cash flow2026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-312024-09-30
Cash from Operations (CFO)($81M)($87M)($64M)($63M)($77M)($95M)($93M)($105M)
Capital Expenditures (CapEx)$0M$1M$1M$0M$0M$0M$0M$1M
Free Cash Flow (FCF)($81M)($87M)($65M)($64M)($77M)($95M)($94M)($106M)
FCF Margin %-181.6%-214.5%-148.2%-175.8%-217.6%-298.6%-245.2%-368.4%

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

GRAL Balance Sheet History

Balance sheet2026-06-302025-12-312024-12-312023-12-312022-12-312021-12-312020-12-312019-12-312018-12-31
Total Assets$2.8B$2.9B$3.0B$4.6B$5.6B$9.7B$706M$636M$687M
Cash & Cash Equivalents$56M$250M$214M$97M$242M$221M$170M$143M$95M
Total Liabilities$301M$344M$480M$911M$956M$307M$144M$85M$86M
Total Debt (Short + Long-Term)$11M$12M$13M$15M$13M$14M$5M$5M$2M
Total Shareholders' Equity$2.5B$2.6B$2.5B$3.6B$4.6B$9.4B$562M$551M$600M

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive GRAL viewer.

Other Companies in DIAGNOSTICS & RESEARCH

← GRAGAll “G” companiesGRAMMY →

About TickerBase · Data methodology & sources · Privacy · Terms

TickerBase is provided for educational and informational purposes only. It does not constitute financial, investment, tax, or legal advice, or a recommendation to buy, sell, or hold any security. No price targets are published; any per-share value shown in the valuation workbench is generated entirely from reader-supplied assumptions and is not the publisher's view of fair value. Past performance does not predict future results. Figures are approximate and drawn from public filings; one-time items are noted where identified. Do your own research and consult a licensed professional before making any investment decision. The author may or may not hold positions in the securities discussed.